A new study showed that compared to non-carriers, ATM, CHEK2, and PALB2 carriers showed similar mortality from breast cancer, pancreatic cancer, and colorectal cancer. Other findings among BRCA1/2 carriers and Lynch Syndrome patients showed: Why is this important?These results may be reassuring for ATM, CHEK2, and PALB2 carriers, and provide additional useful information when discussing …
Permanent link to this article: https://inheritedcancer.net/post060625/
Below is a featured video from the June 2025 case conference, during which Joanne Kotsopoulos, PhD from the Women’s College Hospital discusses hormonal risks in women with hereditary breast and ovarian cancer syndrome.
Permanent link to this article: https://inheritedcancer.net/video61225/
In a recent study based on ICARE participants, we compared cancer risk management between those with CHEK2 1100delC (which leads to moderate breast cancer risk, generally more than 20% lifetime risk) versus I157T (which is a low penetrance mutation, with breast cancer risks of less than 20%) 👩🔬 Of the 150 CHEK2 carriers, there were …
Permanent link to this article: https://inheritedcancer.net/post80524/
Below you may watch a featured video from the October 2022 Genetics Case Conference in which ICARE Principal Investigator, Tuya Pal, MD, discusses recent updates to the National Comprehensive Cancer Network (NCCN) guidelines.
Permanent link to this article: https://inheritedcancer.net/video100622/
